Adamis Pharmaceuticals (ADMP) stock price, revenue, and financials

Adamis Pharmaceuticals market cap is $70.9 m, and annual revenue was $22.11 m in FY 2019

$70.9 M

ADMP Mkt cap, 28-Sept-2020

$3.9 M

Adamis Pharmaceuticals Revenue Q2, 2020
Adamis Pharmaceuticals Gross profit (Q2, 2020)-757.5 K
Adamis Pharmaceuticals Gross profit margin (Q2, 2020), %(19.3%)
Adamis Pharmaceuticals Net income (Q2, 2020)-11.3 M
Adamis Pharmaceuticals EBIT (Q2, 2020)-11.2 M
Adamis Pharmaceuticals Cash, 30-Jun-20207.9 M
Adamis Pharmaceuticals EV68.3 M

Adamis Pharmaceuticals Income Statement

Annual

Adamis Pharmaceuticals Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

7.5k5.4m4.1m4.1m17.3m19.3m8.8m

Accounts Receivable

805.4k830.1k1.2m1.9m

Prepaid Expenses

31.5k64.3k14.5k71.0k474.2k2.1m1.1m

Inventories

942.1k1.8m3.3m2.1m

Current Assets

39.0k350.9k5.4m4.2m21.5m25.8m13.9m

PP&E

92.2k58.3k6.6m9.9m11.7m

Goodwill

7.6m7.6m7.6m7.6m

Total Assets

169.0k350.9k15.1m12.1m37.8m51.4m58.4m47.8m

Accounts Payable

2.0m2.4m671.0k497.8k2.2m2.9m4.2m4.3m

Short-term debt

195.6k97.7k422.0k2.0m2.2m

Current Liabilities

2.9m4.7m2.9m2.7m8.6m8.8m11.6m10.2m

Long-term debt

2.6m

Total Debt

195.6k97.7k383.3k2.6m2.2m

Total Liabilities

12.5m11.9m11.7m11.8m

Common Stock

10.1k11.0k1.1k1.4k3.4k4.8k6.2k

Preferred Stock

101.0

Additional Paid-in Capital

28.1m33.6m58.3m78.3m113.7m153.5m199.7m218.4m

Retained Earnings

(30.8m)(38.0m)(46.1m)(69.0m)(88.5m)(114.0m)(153.0m)(182.3m)

Total Equity

(2.7m)(4.3m)12.2m9.3m25.3m39.5m46.7m36.0m

Debt to Equity Ratio

0 x0.1 x

Debt to Assets Ratio

0 x0.1 x

Financial Leverage

-0.1 x-0.1 x1.2 x1.3 x1.5 x1.3 x1.2 x1.3 x

Quarterly

USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

3.0k1.6k720.0k10.1k1.4k119.6k4.7m2.1m5.9m11.2m8.5m6.3m4.4m417.1k7.8m399.5k10.7m23.3m9.1m3.4m32.0m9.2m4.1m12.1m10.5m7.9m

Accounts Receivable

744.7k595.6k1.2m1.2m1.0m980.8k1.2m1.2m1.8m2.9m2.7m1.3m1.4m

Prepaid Expenses

238.1k117.2k83.6k61.4k104.3k76.0k46.2k67.3k567.4k170.8k265.3k206.2k215.2k209.9k543.5k391.0k1.3m3.1m2.1m1.0m1.0m607.5k

Inventories

1.2m1.1m914.2k950.0k996.1k2.3m2.6m3.2m3.4m2.9m2.5m2.5m2.1m

Current Assets

241.1k118.8k1.7m634.0k790.8k2.2m6.0m11.3m8.5m6.4m5.0m2.6m10.7m3.7m14.1m26.5m13.9m8.7m37.7m17.5m12.0m18.3m15.3m12.0m

PP&E

72.8k68.0k63.1k53.4k5.1m5.0m4.8m5.2m5.8m7.1m8.5m9.2m11.3m11.5m11.6m11.4m11.3m

Goodwill

2.2m2.2m7.6m7.6m7.6m7.6m7.6m7.6m7.6m7.6m7.6m4.5m4.5m

Total Assets

371.1k248.8k1.8m764.0k920.8k3.5m14.8m11.6m15.1m20.0m16.9m14.6m12.7m29.4m36.7m33.7m43.9m56.3m43.8m39.4m70.2m52.7m47.1m52.8m45.3m39.7m

Accounts Payable

1.6m1.7m1.8m1.8m1.9m2.3m1.7m547.7k750.0k977.2k498.0k408.8k1.5m4.2m1.7m2.7m1.9m1.8m2.3m5.2m3.5m4.0m4.3m3.3m3.4m4.3m

Short-term debt

155.6k155.6k155.6k561.3k581.4k4.1m4.1m3.9m2.0m2.0m2.0m2.0m510.8k2.1m2.1m

Current Liabilities

2.4m2.5m6.0m5.8m4.2m2.3m2.1m2.2m4.0m14.3m8.8m9.0m6.5m6.7m7.4m11.1m11.9m11.4m11.5m10.8m10.6m12.4m

Long-term debt

3.2m2.9m2.8m2.7m2.5m2.3m34.0k1.4m2.2m3.2m

Total Debt

155.6k155.6k155.6k561.3k581.4k4.1m4.5m7.3m5.3m5.2m2.5m2.3m34.0k1.9m2.2m2.1m5.3m

Total Liabilities

8.5m4.7m1.9m2.3m12.0m12.8m10.1m10.3m10.3m14.0m12.4m12.9m13.3m12.5m12.1m16.6m

Common Stock

9.6k9.8k10.3k10.4k10.9k1.4k1.4k1.4k1.4k1.8k2.1k2.3k2.8k3.4k3.4k3.4k4.8k4.8k4.8k6.2k7.4k7.4k

Preferred Stock

101.0219.0172.0100.0

Additional Paid-in Capital

26.5m27.3m29.3m29.3m33.1m34.1m54.7m58.7m63.9m76.3m77.1m77.7m84.1m96.2m112.6m115.1m133.0m152.0m155.1m156.7m198.0m201.7m203.4m216.9m225.8m227.0m

Retained Earnings

(28.6m)(29.6m)(33.5m)(34.4m)(36.3m)(39.1m)(44.6m)(49.0m)(51.1m)(58.6m)(62.2m)(65.4m)(75.4m)(81.1m)(87.8m)(94.2m)(99.2m)(106.0m)(121.6m)(131.3m)(140.2m)(161.9m)(169.6m)(176.6m)(192.6m)(203.9m)

Total Equity

(2.0m)(2.3m)(4.3m)(5.1m)(3.2m)9.7m12.8m17.7m14.8m12.3m8.7m15.0m24.8m20.9m33.8m46.0m33.4m25.4m57.8m39.8m33.8m40.3m33.2m23.1m

Debt to Equity Ratio

0.2 x0.3 x0.2 x0.1 x0.1 x0.1 x0 x

Debt to Assets Ratio

0.1 x0.2 x0.1 x0.1 x0.1 x0.1 x0 x

Financial Leverage

-0.2 x-0.1 x-0.4 x-0.2 x-0.3 x1.2 x1.2 x1.1 x1.1 x1.2 x1.5 x2 x1.5 x1.6 x1.3 x1.2 x1.3 x1.5 x1.2 x1.3 x1.4 x1.3 x1.4 x1.7 x

Adamis Pharmaceuticals Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(4.9m)(7.2m)(8.2m)(13.6m)(19.4m)(25.5m)(39.0m)(29.3m)

Depreciation and Amortization

296.1k990.3k2.5m3.1m3.1m2.9m

Accounts Receivable

(363.0k)(87.6k)(421.0k)(745.1k)

Inventories

1.9k(882.5k)(5.0m)24.8k

Accounts Payable

757.5k411.2k(1.8m)(289.2k)(1.7m)587.2k846.1k574.5k

Cash From Operating Activities

(3.3m)(2.6m)(6.8m)(10.3m)(21.2m)(15.1m)(32.7m)(19.9m)

Purchases of PP&E

(121.1k)(2.1m)(3.5m)(2.9m)

Cash From Investing Activities

(10.0m)260.7k(2.1m)(3.5m)(2.9m)

Short-term Borrowings

(390.0k)(539.8k)(6.8m)(324.6k)(2.3m)(487.9k)(430.0k)

Long-term Borrowings

(66.8k)

Cash From Financing Activities

2.1m2.6m22.2m10.6m21.9m30.5m37.1m12.3m

Net Change in Cash

(1.2m)(7.5k)5.4m306.0k1.0m13.2m938.9k(10.5m)

Interest Paid

33.9k120.6k1.2m229.6k216.8k181.3k106.8k

Income Taxes Paid

2.4k19.0k16.7k5.6k9.0k

Quarterly

USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(2.7m)(3.7m)(2.7m)(3.6m)(5.6m)(3.1m)(6.8m)(9.9m)(6.4m)(12.1m)(18.8m)(5.8m)(10.7m)(17.5m)(7.6m)(17.3m)(26.2m)(8.9m)(16.6m)(23.6m)(10.3m)(21.5m)

Depreciation and Amortization

495.1k742.7k247.6k966.6k1.8m782.6k1.6m2.3m770.9k1.5m2.3m791.9k1.5m2.1m917.2k1.8m

Accounts Receivable

(296.6k)(172.7k)(369.9k)(448.7k)(269.2k)(187.3k)(499.6k)(464.6k)(681.2k)(1.8m)(1.5m)548.0k461.4k

Inventories

(282.1k)(112.9k)27.9k(7.9k)(54.0k)(514.7k)(785.3k)(1.4m)(808.2k)(175.2k)(256.3k)(1.0m)(1.6m)

Accounts Payable

366.5k462.8k(203.2k)(176.7k)(79.1k)547.7k750.0k190.2k(289.0k)(378.2k)1.0m316.7k(2.1m)562.9k(256.5k)(400.3k)(1.1m)1.2m603.1k(66.3k)369.6k(420.0k)(736.2k)204.9k

Cash From Operating Activities

(2.0m)(2.7m)(1.2m)(1.9m)(2.5m)(3.2m)(6.0m)(8.1m)(4.7m)(11.1m)(17.9m)(3.5m)(7.0m)(9.9m)(7.9m)(12.4m)(20.4m)(8.3m)(12.7m)(16.9m)(4.2m)(9.4m)

Purchases of PP&E

(16.8k)(16.8k)(48.0k)(615.5k)(1.5m)(201.1k)(1.3m)(3.2m)(1.7m)(2.2m)(2.6m)(274.3k)(660.8k)

Cash From Investing Activities

365.0k365.0k(64.2k)(631.7k)(1.5m)(201.1k)(1.3m)(3.2m)(1.7m)(2.2m)(2.6m)(274.3k)(910.8k)

Short-term Borrowings

(345.0k)(40.0k)(40.0k)(539.8k)(115.3k)(230.9k)(119.7k)(239.8k)(365.0k)(124.2k)(249.1k)(370.8k)(22.4k)(51.1k)

Long-term Borrowings

(17.7k)(36.1k)(54.3k)(1.1k)(2.2k)

Cash From Financing Activities

755.0k1.5m1.9m1.9m2.5m10.6m10.6m10.6m5.0m7.1m21.2m(115.3k)14.3m30.6m(119.7k)(239.8k)37.3m(142.0k)(285.2k)12.4m6.2m9.4m

Net Change in Cash

(1.2m)(1.2m)712.5k2.6k(6.1k)7.5m4.7m2.5m346.2k(3.7m)3.7m(3.7m)6.6m19.2m(8.3m)(13.9m)13.7m9.2m(15.2m)(7.1m)1.7m(919.4k)

Interest Paid

33.9k33.9k13.1k113.7k175.5k39.7k130.9k182.8k50.4k108.8k156.1k24.4k47.0k70.4k39.2k72.1k

Income Taxes Paid

2.4k46.1k4.7k2.4k2.4k912.013.6k13.6k8.7k8.7k9.6k9.7k11.3k

Adamis Pharmaceuticals Ratios

USDQ2, 2012

Financial Leverage

-0.2 x